Notably, inhibitors like PET-16 demonstrate efficacy in reducing mutant BRAF levels and act synergistically with BRAF inhibitors like PLX4032, potentially overcoming resistance encountered in melanoma patients undergoing BRAF inhibitor treatment. The gene discussed is BRAF; the disease is melanoma.